Estuary Biotherapeutics is on a mission to make #ADPKD history through targeted gene therapies designed to address the disease’s underlying genetic cause. Led by CEO Wayne Sackett and built on landmark discoveries from scientific co-founders Stefan Somlo, MD, and Michael Caplan, MD, PhD, at @YaleMed, we're launching with $103 million to advance our lead programs, EST-201 and EST-101, toward clinical proof of concept. Watch our story and learn more at estuarybio.com. estuarybio.com/news/estuary-…